Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CNC Stock Forecast 2025-2026
$37.56
Current Price
$18.46B
Market Cap
Buy 4
Hold 14
Sell 2
Wall St Analyst Ratings
Distance to CNC Price Targets
+86.4%
To High Target of $70.00
+1.2%
To Median Target of $38.00
-25.5%
To Low Target of $28.00
CNC Price Momentum
+6.2%
1 Week Change
-0.7%
1 Month Change
-37.6%
1 Year Change
-38.0%
Year-to-Date Change
-43.8%
From 52W High of $66.81
+49.8%
From 52W Low of $25.08
📊 TOP ANALYST CALLS
Did CNC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Centene is one of their latest high-conviction picks.
Latest CNC Stock Price Targets & Analyst Predictions
Based on our analysis of 36 Wall Street analysts, CNC has a neutral consensus with a median price target of $38.00 (ranging from $28.00 to $70.00). The overall analyst rating is Buy (6.4/10). Currently trading at $37.56, the median forecast implies a 1.2% upside. This outlook is supported by 4 Buy, 14 Hold, and 2 Sell ratings.
The most optimistic forecast comes from Ricky Goldwasser at Morgan Stanley, projecting a 86.4% upside. Conversely, the most conservative target is provided by Ricky Goldwasser at Morgan Stanley, suggesting a 25.5% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CNC Analyst Ratings
4
Buy
14
Hold
2
Sell
CNC Price Target Range
Low
$28.00
Average
$38.00
High
$70.00
Current: $37.56
Latest CNC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CNC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 4, 2025 | Barclays | Andrew Mok | Equal-Weight | Maintains | $44.00 |
| Nov 4, 2025 | JP Morgan | John Stansel | Neutral | Maintains | $38.00 |
| Oct 31, 2025 | TD Cowen | Ryan Langston | Hold | Maintains | $34.00 |
| Oct 31, 2025 | Goldman Sachs | Scott Fidel | Sell | Maintains | $38.00 |
| Oct 30, 2025 | UBS | A.J. Rice | Neutral | Maintains | $42.00 |
| Oct 30, 2025 | Truist Securities | David Macdonald | Buy | Reiterates | $45.00 |
| Oct 30, 2025 | Cantor Fitzgerald | Sarah James | Neutral | Maintains | $41.00 |
| Oct 14, 2025 | Goldman Sachs | Scott Fidel | Sell | Initiates | $33.00 |
| Oct 14, 2025 | Morgan Stanley | Ricky Goldwasser | Equal-Weight | Maintains | $38.00 |
| Oct 9, 2025 | Mizuho | Ann Hynes | Neutral | Maintains | $40.00 |
| Oct 7, 2025 | Wells Fargo | Stephen Baxter | Equal-Weight | Maintains | $41.00 |
| Sep 12, 2025 | Truist Securities | Ryan MacDonald | Buy | Maintains | $39.00 |
| Sep 12, 2025 | Barclays | Andrew Mok | Equal-Weight | Maintains | $35.00 |
| Sep 5, 2025 | Bernstein | Lance Wilkes | Outperform | Maintains | $36.00 |
| Sep 4, 2025 | Barclays | Andrew Mok | Equal-Weight | Maintains | $33.00 |
| Aug 26, 2025 | Cantor Fitzgerald | Sarah James | Neutral | Reiterates | $38.00 |
| Aug 4, 2025 | Morgan Stanley | Ricky Goldwasser | Equal-Weight | Maintains | $28.00 |
| Jul 29, 2025 | JP Morgan | John Stansel | Neutral | Maintains | $30.00 |
| Jul 28, 2025 | UBS | A.J. Rice | Neutral | Maintains | $31.00 |
| Jul 28, 2025 | Cantor Fitzgerald | Sarah James | Neutral | Downgrade | $38.00 |
Centene Corporation (CNC) Competitors
The following stocks are similar to Centene based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Centene Corporation (CNC) Financial Data
Centene Corporation has a market capitalization of $18.46B with a P/E ratio of 8.1x. The company generates $167.68B in trailing twelve-month revenue with a -3.2% profit margin.
Revenue growth is +21.5% quarter-over-quarter, while maintaining an operating margin of +0.5% and return on equity of -21.9%.
Valuation Metrics
Market Cap
$18.46B
Enterprise Value
$16.91B
P/E Ratio
8.1x
PEG Ratio
-0.1x
Price/Sales
0.1x
Growth & Margins
Revenue Growth (YoY)
+21.5%
Gross Margin
+6.0%
Operating Margin
+0.5%
Net Margin
-3.2%
EPS Growth
+22.4%
Financial Health
Cash/Price Ratio
+104.2%
Current Ratio
1.1x
Debt/Equity
83.5x
ROE
-21.9%
ROA
+2.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Centene Corporation (CNC) Business Model
About Centene Corporation
What They Do
Provides managed care services for healthcare programs.
Business Model
Centene Corporation operates primarily through two segments: Managed Care and Specialty Services. It generates revenue by offering health plans and services to government-sponsored healthcare programs, including Medicaid and Medicare Advantage, serving uninsured and underinsured populations.
Additional Information
Founded in 1984 and headquartered in St. Louis, Missouri, Centene is a key player in the healthcare sector, focusing on improving accessibility and affordability. The company enhances healthcare quality through various specialized services such as pharmacy solutions and behavioral health, impacting millions of lives across the United States.
Company Information
Sector
Healthcare
Industry
Healthcare Plans
Employees
60,500
CEO
Ms. Sarah M. London
Country
United States
IPO Year
2001
Website
www.centene.comCentene Corporation (CNC) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Humana Beats Q3 Earnings on Premium Growth, Updates 2025 View
HUM tops Q3 earnings forecasts on strong premium growth, even as higher costs and lower memberships weigh on results.
Nov 05, 2025
By Zacks Equity Research
Analyst Blog
UnitedHealth's Q3 Beat Isn't Stopping the Bleed: Hold or Fold Now?
UNH's Q3 earnings beat couldn't stop a 9.6% stock slide as rising medical costs and margin strain test investor patience.
Nov 05, 2025
By Kaibalya Pravo Dey
Analyst Blog
Can Humana Beat Q3 Earnings Estimates on Growing Premiums?
HUM aims for a Q3 earnings beat as rising premiums and solid service revenues offset higher costs and lower income.
Nov 03, 2025
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
Wellcare, part of Centene Corporation (NYSE: CNC), will provide Medicare Advantage plans to over 51 million beneficiaries in 32 states and nationwide Prescription Drug Plans starting in 2026.
Why It Matters
The expansion of Medicare Advantage plans and Wellcare's transition to integrated D-SNPs indicates growth potential for Centene Corporation, influencing investor confidence and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Centene's Wellcare will provide Medicare Advantage plans in 32 states, including 13 counties in California, starting in 2026, targeting over 51 million beneficiaries.
Why It Matters
Centene's expansion of Wellcare's Medicare Advantage plans boosts its market presence, potentially increasing revenue and attracting more beneficiaries, which positively impacts stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Superior HealthPlan and Centene Foundation announced an investment to combat food insecurity in Texas, addressing challenges from recent disruptions to SNAP and WIC programs.
Why It Matters
Investment in food resources indicates a commitment to social responsibility, potentially enhancing Centene's reputation, customer loyalty, and long-term profitability amidst rising food insecurity.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Meridian Health Plan and Centene Foundation announced an investment to combat food insecurity in Illinois, responding to challenges in access to nutritious food due to disruptions in SNAP and WIC programs.
Why It Matters
The investment by Meridian and Centene addresses rising food insecurity, potentially strengthening community ties and enhancing Centene’s reputation, which can positively impact its stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Starting Nov. 1, 2025, Ambetter from Arizona Complete Health will offer affordable health insurance plans in nine Arizona counties for 2026, under Centene Corporation (NYSE: CNC).
Why It Matters
Centene's expansion of affordable health plans in Arizona may boost its market share and revenue, signaling growth potential and increased demand for healthcare services.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Starting Nov. 1, Ambetter Health will offer affordable plans during open enrollment in 39 counties, providing increased access to health insurance options.
Why It Matters
Ambetter Health's expanded offerings could boost its market share and revenue, impacting stock performance and health sector valuations in the affected counties.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CNC Stock
What is Centene Corporation's (CNC) stock forecast for 2026?
Based on our analysis of 36 Wall Street analysts, Centene Corporation (CNC) has a median price target of $38.00. The highest price target is $70.00 and the lowest is $28.00.
Is CNC stock a good investment in 2026?
According to current analyst ratings, CNC has 4 Buy ratings, 14 Hold ratings, and 2 Sell ratings. The stock is currently trading at $37.56. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CNC stock?
Wall Street analysts predict CNC stock could reach $38.00 in the next 12 months. This represents a 1.2% increase from the current price of $37.56. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Centene Corporation's business model?
Centene Corporation operates primarily through two segments: Managed Care and Specialty Services. It generates revenue by offering health plans and services to government-sponsored healthcare programs, including Medicaid and Medicare Advantage, serving uninsured and underinsured populations.
What is the highest forecasted price for CNC Centene Corporation?
The highest price target for CNC is $70.00 from Ricky Goldwasser at Morgan Stanley, which represents a 86.4% increase from the current price of $37.56.
What is the lowest forecasted price for CNC Centene Corporation?
The lowest price target for CNC is $28.00 from Ricky Goldwasser at Morgan Stanley, which represents a -25.5% decrease from the current price of $37.56.
What is the overall CNC consensus from analysts for Centene Corporation?
The overall analyst consensus for CNC is neutral. Out of 36 Wall Street analysts, 4 rate it as Buy, 14 as Hold, and 2 as Sell, with a median price target of $38.00.
How accurate are CNC stock price projections?
Stock price projections, including those for Centene Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 9, 2025 2:28 AM UTC